Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + SOX as Adjuvant Therapy for Stage N3 Gastric Cancer
NCT07263386Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Started Oct 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT07263386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07263386.